Clinical Trial Update: Comparison of MAPI+Camrelizumab Versus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade Osteosarcoma [Phase 2]

View source ↗

Summary

Phase 2 trial comparing MAPI+camrelizumab, API+apatinib, and MAPI monotherapy in patients with poor response to preoperative chemotherapy for newly diagnosed hi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteosarcoma

Drugs mentioned

• API
• Apatinib (apatinib)
• Camrelizumab (camrelizumab)
• MAPI

Snippet

Sponsor: Peking University People's Hospital | Conditions: Osteosarcoma, Survival | Phase 2 | Status: UNKNOWN